Suratadenoturev - Oncolys Biopharma
Alternative Names: OBP-301; Telomelysin; Telomerase-specific Type 5 Adenovirus OBP-301 - Oncolys BiopharmaLatest Information Update: 03 Feb 2025
At a glance
- Originator Oncolys Biopharma
- Developer Chugai Pharmaceutical; Cornell University; Medigen Biotechnology Corporation; Okayama University; Oncolys BioPharma
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Viral proteins
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Adenocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer
- Phase I/II Liver cancer; Non-small cell lung cancer
- No development reported Adenoid cystic carcinoma; Breast cancer; Mesothelioma; Neuroblastoma; Osteosarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours
Most Recent Events
- 27 Jan 2025 Adverse events data from a phase I trial in Oesophageal cancer and Gastric cancer presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI-2025)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy) in Unknown (Intratumoural, Injection)
- 25 Apr 2024 Oncolys Biopharma initiates a phase II trial in Adenocarcinoma (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT06340711)